Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Articles

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Trial Data Yield Risk-Based NRSTS Treatment Strategies

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

Global CKD Burden Nearly Doubles Since 1990, Reaching 788 Million Adults Worldwide

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

New Proteomic Analysis Maps Cytokine Signatures Driving IPF

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Hearn Jay Cho, MD, PhD, is chief medical officer at the Multiple Myeloma Research Foundation. 

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD